文献速递临床试验与 GCP基础与转化研究

早期与延迟输注恢复期血浆治疗COVID-19住院患者的随机II期临床试验

Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.
PubMed 文献 · PLoS Med · 2021-03-03

在智利单中心开展的开放标签随机II期试验,纳入58例COVID-19症状出现7天内住院、有进展风险因素且未机械通气的患者,比较立即输注恢复期血浆与仅病情恶化时输注。早期血浆组主要复合终点(机械通气、住院>14天或死亡)为32.1%,延迟组为33.3%(OR 0.95,95%CI 0.32-2.84,p>0.999),未见获益。

要点

  • 早期恢复期血浆未降低机械通气、住院>14天或死亡复合终点风险。
  • 院内死亡率早期组17.9% vs 延迟组6.7%,差异无统计学意义。
  • 两组第3天和第7天病毒清除率无显著差异。

核心结论

  • 在COVID-19早期住院患者中,立即加用恢复期血浆相比仅病情恶化时使用,未在死亡率、住院时长或机械通气需求方面发现获益证据。

研究设计与样本

  • 开放标签、单中心、随机II期临床试验,2020年5月10日至7月18日在智利圣地亚哥学术医疗中心开展,最终随访至2020年8月17日。
  • 纳入58例COVID-19症状出现7天内住院、有疾病进展风险因素且未机械通气的患者,随机分为早期血浆组和延迟血浆组。
  • 主要终点为机械通气、住院>14天或死亡的复合终点。

主要发现

  • 早期组主要复合终点发生率32.1%,延迟组33.3%,OR 0.95(95%CI 0.32-2.84),p>0.999。
  • 院内死亡率早期组17.9% vs 延迟组6.7%,OR 3.04(95%CI 0.54-17.17),p=0.246。
  • 机械通气率早期组17.9% vs 延迟组6.7%,OR 3.04(95%CI 0.54-17.17),p=0.246。
  • 延长住院(>14天)早期组21.4% vs 延迟组30.0%,OR 0.64(95%CI 0.19-2.10),p=0.554。
  • 病毒清除率第3天早期组26% vs 延迟组8%(p=0.204),第7天38% vs 19%(p=0.374)。

临床怎么用

  • 对于COVID-19早期住院且有进展风险但未机械通气的患者,立即常规输注恢复期血浆未显示临床获益,可考虑仅在病情恶化时使用。

局限性

  • 研究缺乏统计效力以检测恢复期血浆较小但具有临床意义的疗效。
  • 输注前未确认供者血浆中的中和抗体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Convalescent plasma (CP), despite limited evidence on its efficacy, is being widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to evaluate the efficacy and safety of early CP therapy in COVID-19 progression. METHODS AND FINDINGS: The study was an open-label, single-center randomized clinical trial performed in an academic medical center in Santiago, Chile, from May 10, 2020, to July 18, 2020, with final follow-up until August 17, 2020. The trial included patients hospitalized within the first 7 days of COVID-19 symptom onset, presenting risk factors for illness progression and not on mechanical ventilation. The intervention consisted of immediate CP (early plasma group) versus no CP unless developing prespecified criteria of deterioration (deferred plasma group). Additional standard treatment was allowed in both arms. The primary outcome was a composite of mechanical ventilation, hospitalization for >14 days, or death. The key secondary outcomes included time to respiratory failure, days of mechanical ventilation, hospital length of stay, mortality at 30 days, and SARS-CoV-2 real-time PCR clearance rate. Of 58 randomized patients (mean age, 65.8 years; 50% male), 57 (98.3%) completed the trial. A total of 13 (43.3%) participants from the deferred group received plasma based on clinical aggravation. We failed to find benefit in the primary outcome (32.1% versus 33.3%, odds ratio [OR] 0.95, 95% CI 0.32-2.84, p > 0.999) in the early versus deferred CP group. The in-hospital mortality rate was 17.9% versus 6.7% (OR 3.04, 95% CI 0.54-17.17 p = 0.246), mechanical ventilation 17.9% versus 6.7% (OR 3.04, 95% CI 0.54-17.17, p = 0.246), and prolonged hospitalization 21.4% versus 30.0% (OR 0.64, 95% CI, 0.19-2.10, p = 0.554) in the early versus deferred CP group, respectively. The viral clearance rate on day 3 (26% versus 8%, p = 0.204) and day 7 (38% versus 19%, p = 0.374) did not differ between groups. Two patients experienced serious adverse events within 6 hours after plasma transfusion. The main limitation of this study is the lack of statistical power to detect a smaller but clinically relevant therapeutic effect of CP, as well as not having confirmed neutralizing antibodies in donor before plasma infusion. CONCLUSIONS: In the present study, we failed to find evidence of benefit in mortality, length of hospitalization, or mechanical ventilation requirement by immediate addition of CP therapy in the early stages of COVID-19 compared to its use only in case of patient deterioration. TRIAL REGISTRATION: NCT04375098.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Balcells ME, Rojas L, Le Corre N, et al. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. PLoS Med. 2021. PMID: 33657114. doi:10.1371/journal.pmed.1003415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。